Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers. While conventional technologies, such as FISH and PCR, allow accurate low-throughput detection (e.g., EML4-ALK fusion), next-generation sequencing-based approaches enable comprehensive and simultaneous identification of various alterations (single nucleotide variants, insertions/deletions, fusions, copy number alterations) and genomic signatures (microsatellite instability, tumor mutational burden).
Compared to conventional technologies, NGS-based approaches overcome the challenge of limited materials and reduce the turnaround time. However, further improvements are still needed due to the complex structure of the genome, including repetitive regions and high GC/AT content.
In this webinar, Dr. Judith Müller-Eisert of NEO New Oncology will discuss a collaboration with Agilent Technologies to develop several hybrid capture-based assays for various tumor entities using the SureSelect XT HS2 chemistry. She will share details of the kit’s performance and discuss its use as a powerful tool for cancer profiling.
For Research Use Only. Not for use in diagnostic procedures.